Product and Pipeline Analysis of the Global Parkinson's Disease Therapeutics Market

Product and Pipeline Analysis of the Global Parkinson's Disease Therapeutics Market

RELEASE DATE
04-Feb-2014
REGION
North America
Research Code: MA14-01-00-00-00
SKU: LS00099-NA-MR_16940
AvailableYesPDF Download
$3,950.00
In stock
SKU
LS00099-NA-MR_16940
$3,950.00
DownloadLink
ENQUIRE NOW

Description

This research service focuses on existing therapeutics and product pipeline for the treatment of Parkinson’s Disease using Dopamine Replacement Therapies, Dopamine Agonists, MAO-inhibitors, COMT-inhibitors and other pharamcolgical approaches for current global interest. This research service does not cover vaccines. A product and pipeline assessment is provided for marketed and investigational products and combination regimens for Parkinson’s Disease therapeutics. Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology.

Table of Contents

Executive Summary

Recent Market Developments

Companies to Watch

Key Trends in Parkinson’s Disease Therapeutics

Methodology and Scope

Introduction

Global Prevalence of Parkinson’s Disease by Country

Global Incidence of Parkinson’s Disease by Country

Market Overview—Segmentation by Types of Therapeutics

Market Overview—Segmentation Illustrated

Market Overview—Segmentation Illustrated (continued)

Overview of Market Opportunities

Competitive Landscape—Marketed Products and Products in Development

Marketed Product Synopsis—Parkinson’s Disease Therapeutics

Marketed Product Synopsis—Parkinson’s Disease Therapeutics (continued)

Marketed Product Synopsis—Parkinson’s Disease Therapeutics (continued)

Marketed Product Synopsis—Parkinson’s Disease Therapeutics (continued)

Pipeline Synopsis—Parkinson’s Disease Therapeutics

Pipeline Synopsis—Parkinson’s Disease Therapeutics- Continued

Pipeline Synopsis—Parkinson’s Disease Therapeutics- Continued

Pipeline Synopsis—Parkinson’s Disease Therapeutics- Continued

Parkinson’s Disease Therapeutics Market—Competitive Landscape: Major Ongoing Trials

Competitive Landscape—Projected Launch Timeline for Key Pipeline Drugs

Competitive Landscape—Company Assets by Drug Pipeline Class

Key Marketed Products Dashboard: Stalevo (Carbidopa-Levodopa-Entacapone)—Orion Corporation

Key Marketed Products Dashboard: Sinemet (carbidopa-levodopa)—Merck & Co

Key Marketed Products Dashboard: Azilect (Rasagiline) By TEVA Pharmaceuticals

Key Marketed Products Dashboard: Zelapar (Selagiline) By Valeant Pharmaceuticals

Key Marketed Products Dashboard: Mirapex (Pramipexole) By Boehringer Ingelheim

Key Marketed Products Dashboard: Neupro (Rotigotine) By UCB Inc. and Schwarz Pharma

Key Marketed Products Dashboard: Requip (Ropinirole) By Glaxo SmithKline

Key Phase 3 Products Dashboard:Nouriast® (Istradefylline) By Kyowa Hakko Kirin

Key Phase 2 Products Dashboard:Ampyra® (dalfampridine) By Acorda Therapeutics

Key Phase 3 Products Dashboard:Duodopa® (sinemet) By AbbVie Pharmaceutical

Conclusion

Conclusions (Continued)

Legal Disclaimer

Decision Support Database—Global Population with Parkinson’s Disease

Decision Support Database—Global Population with Parkinson’s Disease (continued)

Who is Frost & Sullivan

What Makes Us Unique

TEAM Methodology

Our Global Footprint 40+ Offices

Related Research
This market insight provides data for the global multiple sclerosis (MS) market. The analysis looks at MS pharmaceutical pipeline drugs that are currently in the market as well as any drugs that are in Phase III trials and pose a potential threat to competitors. It offers a competitive analysis of these drugs and the forecasted outcome and impact of each of these drugs. Injectable drugs dominate MS drugs currently in the market, but the launch of numerous oral pipeline products can shift this market in favor of oral drugs. The MS market is segmented into relapsing, remitting, secondary progressive, primary progressive, and progressive relapsing MS drugs.
More Information
No Index No
Podcast No
WIP Number MA14-01-00-00-00
Is Prebook No